Stockscreener 앱 받기
5.69
2.32%
-0.135
시간 외 거래:
5.97
0.28
+4.92%
전일 마감가:
$5.825
열려 있는:
$5.78
하루 거래량:
52,735
Relative Volume:
1.19
시가총액:
$63.62M
수익:
$3.50M
순이익/손실:
$-43.07M
주가수익비율:
-0.8816
EPS:
-6.4543
순현금흐름:
$-47.84M
1주 성능:
-5.17%
1개월 성능:
-15.07%
6개월 성능:
-31.03%
1년 성능:
+0.00%
1일 변동 폭
$5.35
$6.01
1주일 범위
$5.35
$6.505
52주 변동 폭
$5.35
$17.96
Imagenebio Inc Stock (IMA) Company Profile
명칭
Imagenebio Inc
전화
857-343-8292
주소
12526 HIGH BLUFF DRIVE, SAN DIEGO
Compare IMA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMA
Imagenebio Inc
|
5.69 | 65.13M | 3.50M | -43.07M | -47.84M | -6.4543 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Imagenebio Inc Stock (IMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-25 | 재개 | Wedbush | Underperform |
| 2025-10-24 | 개시 | Leerink Partners | Outperform |
Imagenebio Inc 주식(IMA)의 최신 뉴스
ImageneBio (IMA) CEO receives 128,100 options and 85,400 RSUs - Stock Titan
IMA,CVRX Volatility & Greeks - Finviz
ImageneBio Announces Leadership Transition in Finance Organization - TipRanks
ImageneBio Approves Inducement Grants for New Employees Under Nasdaq Rule 5635(c)(4) - geneonline.com
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
ImageneBio (NASDAQ: IMA) names Bob Lally Principal Accounting Officer as Erin Butler departs - Stock Titan
Two new ImageneBio hires get four-year stock incentive grants - Stock Titan
Atlas Venture Buys Stake in Biotech Firm ImageneBio - National Today
Atlas Venture Life Science Advisors LLC Buys New Position in ImageneBio, Inc. $IMA - Defense World
Wall Street Zen Upgrades ImageneBio (NASDAQ:IMA) to "Hold" - MarketBeat
IMA,CVRX Options - Finviz
Analysts Are Bullish on Top Healthcare Stocks: Opus Genetics (IRD), ImageneBio (IMA) - The Globe and Mail
ImageneBio, Inc. 2025 10-K: IMG-007 Clinical Development, Strategy, and Market Opportunities in Immunological Diseases - Minichart
Legal and Regulatory Risks: How Litigation and Government Actions Could Impact Imagenebio, Inc.’s Financial Performance - TipRanks
ImageneBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
ImageneBio 10-K: License revenue $0.8M; Net loss $45.3M - TradingView
ImageneBio (NASDAQ: IMA) bets on OX40 antibody IMG-007 after Ikena merger - Stock Titan
ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update - The Manila Times
Blue Owl Capital Holdings LP Purchases New Stake in ImageneBio, Inc. $IMA - MarketBeat
ImageneBio Inc expected to post a loss of $1.45 a shareEarnings Preview - TradingView
IMA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
IMA,CVRX Revenue Breakdown - Finviz
ImageneBio to Participate in Leerink Global Healthcare Conference - Eagle-Tribune
BML Capital Management LLC Makes New Investment in ImageneBio, Inc. $IMA - Defense World
ImageneBio (NASDAQ:IMA) Shares Up 2.4% – Still a Buy? - Defense World
ImageneBio announces immediate resignation of board director - TipRanks
ImageneBio (NASDAQ: IMA) prospectus supplement updates resale of 2.5M shares - Stock Titan
ImageneBio, Inc. Announces Resignation of Steven Hui Wang as Member of the Board of Directors, Effective on February 12, 2026 - marketscreener.com
ImageneBio appoints Dr. Porter-Brown as Chief Medical Officer By Investing.com - Investing.com Nigeria
ImageneBio appoints Dr. Porter-Brown as Chief Medical Officer - Investing.com South Africa
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer - marketscreener.com
New ImageneBio CMO to lead late-stage eczema trial using OX40 drug - Stock Titan
ImageneBio Debuts on Nasdaq Following Merger Completion - AD HOC NEWS
ImageneBio (NASDAQ:IMA) Trading Up 0.5%Should You Buy? - MarketBeat
ImageneBio, Inc. (NASDAQ:IMA) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Joseph Slattery Spends US$96k On ImageneBio Stock - simplywall.st
ImageneBio Insider Confidence Rewarded, Stock Hits US$76m Market Cap - Yahoo Finance
Top ImageneBio Insider Makes Bold New Move on Company Stock - TipRanks
Joseph Slattery Buys 16,000 Shares of ImageneBio (NASDAQ:IMA) Stock - MarketBeat
ImageneBio chief medical officer resigns, transition planned - MSN
ImageneBio Chief Medical Officer Resigns, Transition Planned - TipRanks
ImageneBio, Inc. Announces Resignation of Yufang Lu as Chief Medical Officer, effective December 31, 2025 - marketscreener.com
ImageneBio assumed at Underperform from Neutral at Wedbush - MSN
ImageneBio, Inc. (NASDAQ:IMA) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
ImageneBio, Inc. (NASDAQ:IMA) Given Consensus Rating of “Hold” by Brokerages - Defense World
ImageneBio Extends Agreement with Miragene Inc. - MSN
ImageneBio (IMA) price target decreased by 94.20% to 16.32 - MSN
ImageneBio (IMA) Stock Analysis Report | Financials & Insights - Benzinga
ImageneBio, Inc. (IMA) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
ImageneBio, Inc. (IMA) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Wedbush Comments on ImageneBio's Q4 Earnings (NASDAQ:IMA) - MarketBeat
Imagenebio Inc (IMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):